Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jenrin Aims to Resurrect CB-1 Antagonists By Simply Avoiding the Brain

This article was originally published in Start Up

Executive Summary

Jenrin was founded on the idea that adverse psychiatric effects didn't necessarily spell a drug's doom, especially if the medicine did not need to get into the brain in the first place. By tweaking the molecules to prevent their transport across the blood-brain barrier and other physiological hurdles, he hoped to resurrect a number of molecules with potential utility in diseases ranging from dyslipidemia to bowel dysfunction.
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091518

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel